Scancell Holdings Plc Scancell Appoints WG as Joint Broker
March 28 2024 - 9:21AM
RNS Regulatory News
RNS Number : 7606I
Scancell Holdings Plc
28 March 2024
28 March 2024
Scancell Holdings plc
("Scancell" or the
"Company")
WG Partners LLP appointed as Joint
Broker
Scancell Holdings plc (AIM:
SCLP), the developer of novel immunotherapies for the treatment of
cancer, announces that WG Partners LLP was appointed as Joint
Broker to the Company on the 3 October 2023.
-ENDS-
|
For further
information, please contact:
|
|
|
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive
Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment
Banking)
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
|
WG Partners
LLP (Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Sathesh Nadarajah/Erland
Sternby
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this
includes citrullination and homocitrullination of proteins, whereas
its mAb portfolio targets glycans or sugars that are added onto
proteins and / or lipids (GlyMab®) or enhances the
potency of antibodies and their ability to directly kill tumour
cells (AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPEADDPAFXLEFA
Scancell (LSE:SCLP)
Historical Stock Chart
From Dec 2024 to Jan 2025
Scancell (LSE:SCLP)
Historical Stock Chart
From Jan 2024 to Jan 2025
